Eli Lilly and Company to invest US$1.2 billion in Puerto Rico manufacturing hub

Eli Lilly announced it will invest more than US$1.2 billion to expand its manufacturing site in Carolina, Puerto Rico, part of a broader push to bolster U.S. production capacity amid global supply-chain pressures and tariff risks. The upgraded facility will support the company’s upcoming weight-loss pill, Orforglipron, plus heart, diabetic, cancer and immune disorder treatments. Construction starts in 2026 with production by end-2028; the investment is part of Lilly’s previously announced ~US$50 billion U.S. manufacturing expansion plan.